Immediate Detection of Helicobacter Infection With a New Electrochemical System.
1 other identifier
interventional
120
1 country
1
Brief Summary
Helicobacter pylori-infection (H. pylori) affects about fifty percent of the general population and is associated with peptic ulcer disease, non-cardia gastric adenocarcinoma and gastric lymphoma. Currently, diagnostic methods include breath tests, serology, stool antigen tests, histology or the Helicobacter urease test (HUT). The aim of our study is to access the clinical reliability of a new, electrochemical device for rapid H. pylori detection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2009
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2009
CompletedFirst Submitted
Initial submission to the registry
November 2, 2010
CompletedFirst Posted
Study publicly available on registry
November 4, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2013
CompletedDecember 14, 2020
December 1, 2020
3.3 years
November 2, 2010
December 10, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Effectiveness of the newly developed device in comparison to IHC, HUT and C13-urea breath test.
Oktober 2009 - February 2011
Study Arms (2)
H. pylori positive patients
OTHERH. pylori negative patients
OTHERInterventions
Determination of H. pylori infection.
Determination of H. pylori infection.
Determination of H. pylori infection.
Determination of H. pylori infection.
Eligibility Criteria
You may qualify if:
- Written informed consent
- Age 18-85 years
- Ability of subjects to understand character and individual consequences of clinical trial
- Subjects undergoing EGD
You may not qualify if:
- Inability to provide written informed consent
- Severe Coagulopathy (Prothrombin time \< 50% of control, Partial thromboplastin time \> 50 s)
- Pregnancy or breast feeding
- Active gastrointestinal bleeding
- Residing in institutions (e.g. prison)
- PPI intake
- antibiotic use, actual or within the last 4 weeks
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Erlangen-Nuremberg
Erlangen, Bavaria, 91054, Germany
Study Officials
- STUDY DIRECTOR
Markus F. Neurath, M.D., Ph.D.
University of Erlangen-Nürnberg
- PRINCIPAL INVESTIGATOR
Helmut Neumann, M.D., Ph.D.
University of Erlangen-Nürnberg
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 2, 2010
First Posted
November 4, 2010
Study Start
October 1, 2009
Primary Completion
January 1, 2013
Study Completion
January 1, 2013
Last Updated
December 14, 2020
Record last verified: 2020-12